More and more, the quality of real-world evidence (RWE)—gathered from remote patient monitoring data, product and disease registry data, and patient feedback—determines whether a medical device is approved and, in some instances, for how long. Yet some medical device manufacturers are missing an important opportunity to collaborate with clinical registries in capturing this data and driving value.
“We are honored to have Dr. Lace, who is widely recognized as one of the industry’s most trusted reimbursement experts, leading our new division. He will also support all our services as our CMO.”
A review of the top six reasons there has been a dramatic increase in the adoption of remote care among seniors.
The short answer is yes, but doing your homework in advance is now more important than ever.
China’s medical device market has grown significantly over the last five years, but with that growth comes some pitfalls.
Although opportunities in Japan are still considerable, foreign device companies need to do their homework to be successful.
As restrictions lift and in-person visits become viable again, the use of virtual care technology — particularly telemedicine and remote patient monitoring (RPM)—is here to stay.
Its success lies in a synergy between the technological and the clinical.
COVID-19 is driving patients to seek telehealth solutions, and it won’t be a short-term boom.
A look at IP litigation in 2019 and the year ahead, and some advice on how medical device companies can safeguard their intellectual property.